MUC1 and neoplasm: More recently, a therapeutic regimen of AR20.5 in combination with anti-programmed death-ligand (anti-PD-L1) and polyinosinic-polycytidylic acid (PolyICLC) was explored in mouse models of pancreatic cancer and was found to produce MUC1-specific immune responses that suppress tumor growth [34].